
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria
Keywords: عارضه جانبی یا عوارض جانبی; Chronic idiopathic urticaria; chronic spontaneous urticaria; H1-antihistamine; hive; itch; omalizumab; urticaria activity score; dose ranging; AE; Adverse event; CIU; Chronic idiopathic urticaria; nsAH; Nonsedating H1-antihistamine; UAS; Urticaria activit